30 August 2024
Advanced
Medical Solutions Group plc
("AMS" or
the "Group")
Total Voting
Rights
In accordance with
Disclosure and Transparency Rule 5.6.1, the issued share capital of
Advanced Medical Solutions Group plc as at 30 August 2024
comprises 217,679,768
ordinary shares of 5p each with
voting rights. There are no shares held in
treasury.
The above figure may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure and Transparency Rules.
- End -
For
further information, please visit www.admedsol.com
or
contact:
Advanced Medical Solutions Group plc
|
Tel: +44
(0) 1606 545508
|
Chris Meredith, Chief Executive
Officer
Eddie Johnson, Chief Financial
Officer
Michael King, Investor
Relations
|
|
|
|
ICR
Consilium
|
Tel: +44
(0) 20 3709 5700
|
Mary-Jane Elliott
/ Lucy Featherstone
|
AMS@consilium-comms.com
|
|
|
Investec Bank PLC (NOMAD & Broker)
|
Tel: +44
(0) 20 7597 5970
|
Gary Clarence / David
Anderson
|
|
HSBC Bank plc (Broker)
|
Tel: 44
(0) 20 7991 8888
|
Joe Weaving / Stephanie
Cornish
|
|
About Advanced Medical Solutions Group plc
-
see www.admedsol.com
AMS is a world-leading independent
developer and manufacturer of innovative tissue-healing technology,
focused on quality outcomes for patients and value for payers. AMS
has a wide range of surgical products including tissue adhesives,
sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver
alginates, alginates and foams through its ActivHeal® brand as well
as under white label. Since 2019, the Group has made seven
acquisitions: Sealantis, an Israeli developer of innovative
internal sealants, Biomatlante, a French developer and manufacturer
of surgical biomaterials, Raleigh, a leading UK coater and
converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish
tissue adhesives specialist, Syntacoll, a German specialist in
collagen-based absorbable surgical implants and Peters Surgical, a
global provider of specialty surgical sutures, mechanical
haemostasis and internal cyanoacrylate devices.
AMS's products, manufactured in the
UK, Germany, France, the Netherlands, Thailand, India, the Czech
Republic and Israel, are sold globally via a network of
multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France,
Poland, Benelux, India, the Czech Republic and Russia. The Group
has R&D innovation hubs in the UK, Ireland, Germany, France and
Israel. Established in 1991, the Group has more than 1,500
employees. For more information, please see
www.admedsol.com.
-